Journal Article

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

Marsall, Patrick, Metzdorf, Kristin, Häring, Julia, Cicin-Sain, Luka, Lüddecke, Tatjana, Castell, Stefanie, Hoffmann, Markus, Schneiderhan-Marra, Nicole, Katzmarzyk, Maeva, Abassi, Leila, Melhorn, Vanessa, Maaß, Henrike, Ortmann, Julia, Harries, Manuela, Junker, Daniel, Ynga Durand, Mario Alberto, Strengert, Monika, Gornyk, Daniela, Rand, Ulfert, Kim, Yeonsu, Jacobsen, Henning, Krause, Gérard, Dulovic, Alex, Kessel, Barbora, Hernandez, Pilar, Glöckner, Stephan, Heise, Jana-Kristin, Kemmling, Yvonne, Lange, Berit, Pöhlmann, Stefan

2022

Overview

SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-induced protection against infection. The novel variant of concern (VoC) Omicron BA.1 and its sub-lineages have the largest number of amino acid alterations in its Spike protein to date. Thus, they may efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in convalescent and vaccinated individuals in particular in those who have only received a primary immunization scheme. We analyzed neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous immunization schemes currently available in Europe by in vitro neutralization assay at peak response towards SARS-CoV-2 B.1, Omicron sub-lineages BA.1, BA.2, BA.2.12.1, BA.3, BA.4/5, Beta and Delta pseudotypes and also provide longitudinal follow-up data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (96–100%) towards the SARS-CoV-2 B.1 isolate, and minor to moderate reductions in neutralizing Beta and Delta VoC pseudotypes. The novel Omicron variant and its sub-lineages had the biggest impact, both in terms of response rates and neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron BA.1 and induced the highest level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous BNT162b2 vaccination, vector-based AZD1222 and Ad26.CoV2.S performed less well with peak responder rates of 48%, 56% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-protection against Omicron maintain it over time. Overall, our data strongly argue for booster doses in individuals who were previously vaccinated with BNT162b2, or a vector-based primary immunization scheme.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 631/250 / 631/250/2161 / 631/250/254 / 631/250/255/2514 / 631/250/590 / 631/250/590/2293 / 631/326 / 631/326/2521 / 631/326/421 / 631/326/590 / 631/326/596 / 631/326/596/4130 / Ad26COVS1 / Amino acids / Antibodies, Viral / BNT162 Vaccine / ChAdOx1 nCoV-19 / COVID-19 / COVID-19 - prevention & control / COVID-19 Vaccines / Cross-protection / Humanities and Social Sciences / Humans / Immunization / mRNA / multidisciplinary / Neutralization / Neutralization Tests / RNA, Messenger / SARS-CoV-2 - genetics / Science / Science (multidisciplinary) / Severe acute respiratory syndrome coronavirus 2 / Spike protein / Vaccination / Vaccines